Susquehanna International Group
SNDX icon

Susquehanna International Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Susquehanna International Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33M Sell
142,700
-119,800
-46% -$2.6M ﹤0.01% 5055
2025
Q4 		$5.52M Sell
262,500
-16,800
-6% -$293K ﹤0.01% 3861
2025
Q3 		$4.3M Buy
279,300
+20,900
+8% +$274K ﹤0.01% 4338
2025
Q2 		$2.42M Buy
258,400
+35,700
+16% +$393K ﹤0.01% 5382
2025
Q1 		$2.74M Buy
222,700
+180,600
+429% +$2.55M ﹤0.01% 4849
2024
Q4 		$557K Sell
42,100
-158,300
-79% -$2.71M ﹤0.01% 8411
2024
Q3 		$3.86M Buy
200,400
+171,000
+582% +$3.53M ﹤0.01% 4072
2024
Q2 		$604K Sell
29,400
-71,300
-71% -$1.49M ﹤0.01% 7812
2024
Q1 		$2.4M Sell
100,700
-47,900
-32% -$1.07M ﹤0.01% 4950
2023
Q4 		$3.21M Sell
148,600
-545,200
-79% -$8.38M ﹤0.01% 4453
2023
Q3 		$10.1M Buy
693,800
+590,800
+574% +$11.2M ﹤0.01% 2565
2023
Q2 		$2.16M Buy
+103,000
New +$2.14M ﹤0.01% 4999
2023
Q1 		– Sell
-73,100
Closed -$1.86M – 13438
2022
Q4 		$1.86M Buy
73,100
+54,800
+299% +$1.28M ﹤0.01% 4840
2022
Q3 		$440K Sell
18,300
-1,500
-8% -$33.7K ﹤0.01% 8822
2022
Q2 		$381K Buy
+19,800
New +$330K ﹤0.01% 8921
2022
Q1 		– Sell
-19,300
Closed -$422K – 13905
2021
Q4 		$422K Buy
19,300
+6,900
+56% +$127K ﹤0.01% 9619
2021
Q3 		$237K Sell
12,400
-54,600
-81% -$910K ﹤0.01% 11123
2021
Q2 		$1.15M Sell
67,000
-35,400
-35% -$648K ﹤0.01% 7376
2021
Q1 		$2.29M Buy
102,400
+9,300
+10% +$210K ﹤0.01% 5603
2020
Q4 		$2.07M Buy
93,100
+57,600
+162% +$1.19M ﹤0.01% 5022
2020
Q3 		$524K Sell
35,500
-54,700
-61% -$834K ﹤0.01% 7565
2020
Q2 		$1.34M Buy
90,200
+74,700
+482% +$1.14M ﹤0.01% 5272
2020
Q1 		$170K Sell
15,500
-89,500
-85% -$840K ﹤0.01% 8876
2019
Q4 		$922K Sell
105,000
-9,000
-8% -$66.1K ﹤0.01% 5688
2019
Q3 		$852K Buy
114,000
+56,000
+97% +$510K ﹤0.01% 6050
2019
Q2 		$540K Buy
+58,000
New +$423K ﹤0.01% 7100
2019
Q1 		– Sell
-14,100
Closed -$63K – 9770
2018
Q4 		$63K Sell
14,100
-39,400
-74% -$216K ﹤0.01% 8403
2018
Q3 		$432K Buy
53,500
+7,800
+17% +$55.6K ﹤0.01% 6801
2018
Q2 		$321K Buy
45,700
+18,300
+67% +$180K ﹤0.01% 7702
2018
Q1 		$390K Buy
+27,400
New +$291K ﹤0.01% 7144

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Susquehanna International Group's SNDX Position: Q1 2026 in Review

Susquehanna International Group increased its Syndax Pharmaceuticals (SNDX) stake by 983% in Q1 2026, buying an estimated $3.88M and bringing the position to 196,621 shares worth $4.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4382.

Susquehanna International Group first reported a position in SNDX in Q3 2018 and has held it in 25 quarters since. The position peaked at $17.5M in Q1 2024. 247 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Susquehanna International Group held 196,621 shares of Syndax Pharmaceuticals worth $4.59M as of Q1 2026.
  • Susquehanna International Group bought 178,468 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.88M.
  • Syndax Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4382 holding.
  • Susquehanna International Group first reported a position in Syndax Pharmaceuticals in Q3 2018 and has held it in 25 quarters since.
  • Susquehanna International Group's Syndax Pharmaceuticals position peaked at $17.5M in Q1 2024.
  • 247 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.